Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise

June 12, 2015 |  Contributor: Eamonn O'Connor, Ph.D.

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT ...

FDA advisory panel approves novel cholesterol-lowering drug

June 10, 2015 | Honor Whiteman, Medical News Today

An advisory committee for the Food and Drug Administration has recommended the approval of a novel, injectable cholesterol-lowering drug called alirocumab, though many committee members have noted certain restrictions for its use and have requested further data on the drug's ability to reduce the risk of heart problems.

According to the Centers for Disease Control and Prevention (CDC), around 73.5 million people in the US have high levels of "bad" cholesterol ...

A step towards a type 1 diabetes vaccine by using nanotherapy

June 10, 2015 | Released by Universitat Autonoma de Barcelona

Two years ago, the Immunology of Diabetes Research Group at the Germans Trias Research Institute (at Universitat Autònoma de Barcelona - Campus of International Excellence Sphere) reported a new experimental immunotherapy that prevented the onset of Type 1 Diabetes in mice predisposed to the disease ...

Vigilant Biosciences Announces Agreement with Eurobio for Exclusive Distribution of the OncAlert™ Oral Cancer Risk Assessment System in France, Algeria, Morocco and Tunisia

June 10, 2015 | Vigilant Biosciences, Inc

Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer ...